Drug
Aprepitant clinical trials
Also written Emend, MK0869 and ONO-7436.
- studies test it
- 129
- open now
- 7
- in phase 3
- 35
- first study started
- 2001
Keep track of what changes. Save the Aprepitant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Emend
- 48
Studies by the year they started
128 studies that test it; most in 2011 (13)
| Year | Studies |
|---|---|
| 2001 | 5 |
| 2002 | 4 |
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 4 |
| 2007 | 9 |
| 2008 | 7 |
| 2009 | 8 |
| 2010 | 10 |
| 2011 | 13 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 8 |
| 2015 | 8 |
| 2016 | 3 |
| 2017 | 6 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 14
- Phase 2
- 27
- Phase 3
- 35
- Phase 4
- 30
- No phase
- 22
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 104
Merck Sharp & Dohme LLC (19) · Sun Yat-sen University (4) · University of Pennsylvania (4) · The Hospital for Sick Children (2) · Vanderbilt University (2) · NYU Langone Health (2) · Mayo Clinic (2) · Dartmouth-Hitchcock Medical Center (2)
Often tested with
Tested in the same studies.
Dexamethasone (20) · Ondansetron (13) · Fosaprepitant (8) · Palonosetron (7) · Granisetron (4) · Ramosetron (4) · Olanzapine (3) · Cyclophosphamide (2)
Studies
Open first, then newest update. How each study uses Aprepitant is read from its arms, and is right about nine times in ten.
Testing it · 129
- Aprepitant for the Treatment of CLIFAHDDRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT07845825Written as Aprepitant Powder for Oral Suspension
- Aprepitant to Improve Same Day Discharge for TKANot yet recruitingPhase 4Endeavor HealthNCT07639723Written as Aprepitant Injection
- Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis SurgeryRecruitingPhase 2IWK Health CentreNCT06357234Written as Aprepitant
- Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryNot yet recruitingPhase 4Sir Mortimer B. Davis - Jewish General HospitalNCT07371728Written as Aprepitant
- Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer PatientsNot yet recruitingPhase 1Rabin Medical CenterNCT06931119Written as EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT06543966Written as Aprepitant Injection
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerNot yet recruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05841849Written as Aprepitant
- Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical PatientsCompletedPhase 3Centre hospitalier de l'Université de Montréal (CHUM)NCT07248280Written as Aprepitant 40mg
- Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated DataCompletedPhase 3Jennifer Holder-MurrayNCT04606264Written as Aprepitant
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3CompletedPhase 4Yale UniversityNCT04649229Written as Aprepitant
- Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedPhase 3Sichuan Cancer Hospital and Research InstituteNCT06007586Written as Aprepitant Injection
- Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative NeoplasmsCompletedPhase 3University Hospital, BrestNCT03808805Written as Aprepitant 80 mg
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and VomitingCompletedPhase 3Qilu Pharmaceutical (Hainan) Co., Ltd.NCT06932107Written as Aprepitant Injection
- Topical Aprepitant in Prurigo PatientsCompletedPhase 2LEO PharmaNCT01963793Written as Aprepitant
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery.TerminatedPhase 4Insel Gruppe AG, University Hospital BernNCT05189756Written as Aprepitant 80 mg
- Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary DysmenorrheaCompletedPhase 3Lahore Medical Research Center, LLPNCT06317064Written as Ibuprofen and Aprepitant
- Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid CancerCompletedPhase 4The First Affiliated Hospital of Zhengzhou UniversityNCT06697782Written as Aprepitant 125 mg
- Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast CancerCompletedPhase 1UNC Lineberger Comprehensive Cancer CenterNCT00719173Written as aprepitant
- Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose MelphalanCompletedPhase 3Rush University Medical CenterNCT02939287Written as o Aprepitant 125 mg orally one hour prior to chemotherapy on Day -1 and 80 mg orally on Days 0 and +1
- Comparison of Adding EMEND to PONV/PDNV Treatment RegimenWithdrawnNot applicableUniversity of NebraskaNCT01186029Written as aprepitant
See all 129 studies that test Aprepitant →
Given in every arm · 13 — Aprepitant is usual care beside what is tested
- Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 BlockadeRecruitingNot applicableHubei Cancer HospitalNCT06080880Written as Aprepitant
- Phase 2 Bunionectomy HTX-011 Administration StudyCompletedPhase 2Heron TherapeuticsNCT03718039Written as aprepitant
- Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and AdolescentsStatus unknownPhase 3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT05346731Written as Aprepitant
- Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed EmesisCompletedPhase 3Fudan UniversityNCT02336750Written as Aprepitant
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent GlioblastomaCompletedPhase 1/2University of UlmNCT02770378Written as Aprepitant
- Granisetron Transdermal Patch for Prophylaxis of Delayed CINVStatus unknownPhase 3Fudan UniversityNCT04912271Written as Aprepitant
- "Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"CompletedPhase 3All India Institute of Medical Sciences, New DelhiNCT03219710Written as Aprepitant
- Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)CompletedPhase 1Merck Sharp & Dohme LLCNCT00871910Written as Aprepitant
- Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus AprepitantCompletedNot applicableKyungpook National University HospitalNCT02597907Written as aprepitant
- Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and VomitingCompletedPhase 3First Affiliated Hospital of Harbin Medical UniversityNCT02484911Written as Aprepitant
- Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)CompletedNot applicableOhio State University Comprehensive Cancer CenterNCT01640340Written as aprepitant
- Aprepitant in the Management of Biological Therapies-related Severe PruritusCompletedPhase 2Campus Bio-Medico UniversityNCT01683552Written as Aprepitant
- Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic SurgeriesStatus unknownNot applicableMain Line HealthNCT00835965Written as Aprepitant
As the comparator · 11 — what is tested is compared with Aprepitant
- QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous AdministrationNot yet recruitingPhase 1Qilu Pharmaceutical (Hainan) Co., Ltd.NCT07817004Written as apripitant injection (CINVANTI)
- A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving ChemotherapyNot yet recruitingEarly Phase 1Ottawa Hospital Research InstituteNCT07662200Written as Aprepitant
- Feasibility of Olanzapine at REduced doSe in hIGHly Emetogenic chemoTherapyCompletedPhase 3CR-CSSS Champlain-Charles-Le MoyneNCT04075955Written as Emend® (Aprepitant)
- Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic ChemotherapyStatus unknownPhase 3Mahidol UniversityNCT03876938Written as aprepitant
- Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent NauseaCompletedPhase 4Loyola UniversityNCT00781768Written as Aprepitant (MK-869) + Standard PO
- Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) ProphylaxisStatus unknownPhase 2Blokhin's Russian Cancer Research CenterNCT03478605Written as Aprepitant Pill
- Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)CompletedPhase 3Merck Sharp & Dohme LLCNCT00619359Written as Comparator: Aprepitant
- Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical TrialCompletedPhase 3Joseph RoscoeNCT00475085Written as aprepitant
- Ondansetron Versus Aprepitant Plus Ondansetron for EmesisCompletedPhase 2M.D. Anderson Cancer CenterNCT00954941Written as Aprepitant
- A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)CompletedPhase 1Merck Sharp & Dohme LLCNCT00945321Written as aprepitant 165 mg
- A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedPhase 3Helsinn Healthcare SANCT01376297Written as Aprepitant
Codes
What other systems call Aprepitant · ClinicalTrials.gg INT006778
- MeSH (NLM) D000077608AprepitantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 1NF15YR6UYAPREPITANTConfirmed FDA, NLM, Wikidata
- RxNorm 358255Confirmed FDA, Wikidata
- Wikidata Q621834aprepitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49173AprepitantOne source FDA
- DrugBank DB00673One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077608 | Aprepitant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 1NF15YR6UY | APREPITANT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 358255 | — | Confirmed FDA, Wikidata |
| Wikidata | Q621834 | aprepitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49173 | Aprepitant | One source FDA |
| DrugBank | DB00673 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.